Back to top
more

OraSure Technologies (OSUR)

(Delayed Data from NSDQ)

$3.12 USD

3.12
579,261

+0.11 (3.65%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $3.12 0.00 (0.00%) 5:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of -20% and 0.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Envista (NVST) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 20% and 1.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 11.94% and 2.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GE HealthCare (GEHC) Surges 10.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

GE HealthCare (GEHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

OraSure Technologies (OSUR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of -200% and 2.27%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insulet (PODD) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BellRing Brands (BRBR) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

BellRing Brands (BRBR) delivered earnings and revenue surprises of 23.40% and 1.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OraSure (OSUR) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

OraSure (OSUR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

New Strong Buy Stocks for January 27th

by Zacks Equity Research

ALNY, HBT, APH, GNTY and OSUR have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2024.

Zacks Equity Research

Should Value Investors Buy OraSure Technologies (OSUR) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

David Bartosiak headshot

Bear of the Day: Baxter (BAX)

by David Bartosiak

The recent earnings trend has been troubling. Can the company turn it around next year?

Zacks Equity Research

New Strong Buy Stocks for January 16th

by Zacks Equity Research

MRCY, BBCP, OSUR, VIK and IFS have been added to the Zacks Rank #1 (Strong Buy) List on January 16, 2025.

Zacks Equity Research

Are Investors Undervaluing OraSure Technologies (OSUR) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

OSUR Stock Rises Following the Acquisition of Sherlock Biosciences

by Zacks Equity Research

OraSure announces acquisition of Sherlock Biosciences to strengthen its molecular diagnostics portfolio.

Zacks Equity Research

Should Value Investors Buy biote Corp. (BTMD) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is OraSure Technologies (OSUR) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is OraSure Technologies (OSUR) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Phibro Animal Health Corporation (PAHC) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Phibro (PAHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of 75% and 1.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OraSure Technologies (OSUR) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of 133.33% and 1.86%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OraSure Technologies (OSUR) Q1 Earnings Meet Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of 0% and 3.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of 108.96% and 10.79%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 2.33% and 2.28%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Abbott (ABT) Q4 Earnings Match Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 0% and 0.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron

by Zacks Equity Research

Otter Tail, OraSure, BioMarin and Regeneron have been highlighted in this Screen of The Week article.